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Abstract
The purpose of the study was to determine the specific periods during pregnancy in which human
fetal exposure to stress hormones affects newborn physical and neuromuscular maturation. Blood
was collected from 158 women at 15, 19, 25, and 31 weeks’ gestation. Levels of placental
corticotropin-releasing hormone (CRH) and maternal cortisol were determined from plasma.
Newborns were evaluated with the New Ballard Maturation Score. Results indicated that increases
in maternal cortisol at 15, 19, and 25 weeks and increases in placental CRH at 31 weeks were
significantly associated with decreases in infant maturation among males (even after controlling for
length of gestation). Results also suggested that increases in maternal cortisol at 31 weeks were
associated with increases in infant maturation among females, although these results were not
significant after controlling for length of gestation. Findings suggest that stress hormones have effects
on human fetal neurodevelopment that are independent of birth outcome.
Keywords
fetal; HPA-axis; cortisol; CRH; pregnancy; fetus; New Ballard Maturation Score; stress; infant;
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INTRODUCTION
Insults or disruptions of normal fetal maturation can lead to long-lasting neurobiological and
health outcomes that persist across the lifespan. Barker’s (1995) pivotal studies linking adverse
birth outcomes, such as low birth weight, to adult diseases promoted the idea that vulnerabilities
to mental and physical diseases could be programmed during the fetal period. Deleterious birth
outcomes likely reflect aberrant processes beginning in intrauterine development that may
contribute to health and disease risk later in life (Gluckman & Hanson, 2004; Maccari et al.,
2003). One emerging area of interest is the effects of maternal stress on the intrauterine
environment and its consequences for fetal and infant development.
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The fetus is involved in a dynamic communication with the mother over the course of gestation,
including exchanges in markers of biological stress that originate from the maternal-placental-
fetal unit. One of the major placental stress signals in pregnant primates is the peptide
corticotropin-releasing hormone (CRH). This peptide plays a key role in the maturation of the
fetal hypothalamic-pituitary-adrenal-axis (HPA-axis) and other systems, and coordinates
events that underlie both fetal growth and maturation and the time of onset of parturition
(Hobel, Dunkel-Schetter, Roesch, Castro, & Arora, 1999; Sandman et al., 2006; Sandman et
al., 2003; Sandman, Wadhwa, Chicz-DeMet, Porto, & Garite, 1999; Sandman et al., 1999b;
Wadhwa et al., 2004; Wadhwa, Porto, Garite, Chicz-DeMet, & Sandman, 1998).
The HPA-axis during pregnancy in human and nonhuman primates is significantly different
than that of nonpregnant adult primates. In contrast to the typical suppressive effects of
glucocorticoids on CRH synthesis in the hypothalamus, there is a positive feedback loop
between placental CRH and cortisol from the adrenal cortex of the mother (Jones, Brooks, &
Challis, 1989; King, Smith, & Nicholson, 2001; Trainer, 2002). The difference in behavior of
the CRH gene in the placenta and hypothalamus is due to the expression of different
transcription factors, coactivators, and corepressors in these two tissues (King, Smith, &
Nicholson, 2002). Subsequently, levels of both CRH and cortisol rise steadily throughout
gestation (Gemzell, 1953; Goland, Wardlaw, Blum, Tropper, & Stark, 1988). Despite increases
in cortisol in maternal serum during pregnancy, only 10–20% of maternal cortisol crosses the
placenta to reach fetal circulation in humans between 13 and 35 weeks’ gestation
(Benediktsson, Calder, Edwards, & Seckl, 1997; Gitau, Cameron, Fisk, & Glover, 1998;
Sandman et al., 2003). The enzyme 11β-hydroxysteroid dehydrogenase-2 (11β-HSD-2) has
been isolated in the human placenta and likely accounts for the relatively low transfer of
maternal cortisol to the fetus by converting cortisol to its inactive form cortisone (Benediktsson
et al., 1997; Bernal, Flint, Anderson, & Turnbull, 1980). 11β-HSD-2 shows steady increases
throughout gestation until the last few weeks of gestation when decreases in 11β-HSD-2 are
observed (Lopez Bernal, Anderson, & Turnbull, 1982; Murphy & Clifton, 2003; Sandman et
al., 2003; Schoof et al., 2001; Shams et al., 1998). Although, 11β-HSD-2 provides protection
for the fetus from maternal cortisol, it does not provide complete protection; thus, some
maternal cortisol continues to reach the fetus.
Fetal exposure to glucocorticoids and CRH has both beneficial and detrimental consequences
for fetal growth and maturation. Specifically, during the last trimester of pregnancy, exposure
to cortisol is critical for the maturation of fetal physiological systems and organs, such as the
cardiovascular system, the pulmonary system, renal systems, and overall fetal growth (Murphy,
Smith, Giles, & Clifton, 2006; Trainer, 2002; Welberg, Seckl, & Holmes, 2001). Despite the
necessity of cortisol for fetal maturation, it has been repeatedly demonstrated that women
receiving synthetic corticosteroids (administration commencing typically around the 24th
week gestation) were more likely to deliver infants with fetal growth restriction and low birth
weight, even when controlling for length of gestation, suggesting that high levels of
glucocorticoids may be detrimental to fetal growth (Bloom, Sheffield, McIntire, & Leveno,
2001; French, Hagan, Evans, Godfrey, & Newnham, 1999; Reinisch, Simon, Karow, &
Gandelman, 1978). Similarly, exposure to CRH at 33 weeks’ gestation has been associated
with fetal growth restriction (Wadhwa et al., 2004). Nevertheless, no study has examined
whether the timing of prenatal exposure to stress hormones affects fetal growth and maturation.
Stress hormones also have been consistently associated with preterm delivery and shorter
gestational periods (Hobel et al., 1999; Mancuso, Schetter, Rini, Roesch, & Hobel, 2004;
Mullings et al., 2001; Sandman et al., 2006; Sandman et al., 1994; Wadhwa, Sandman, Porto,
Dunkel-Schetter, & Garite, 1993). In addition, the timing of exposure to stress hormones during
pregnancy may be critical in determining the length of gestation. Specifically, recent evidence
suggests that elevated maternal cortisol at 15 weeks’ gestation led to a surge of placental CRH
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at 31 weeks’ gestation, which, in turn, was associated with preterm delivery (Sandman et al.,
2006). These data suggest that a stress-related signal early in pregnancy could prepare the
placenta to activate labor-inducing signaling mechanisms later in gestation.
Cumulatively, the existing empirical findings suggest that fetal exposure to elevated levels of
stress hormones leads to shortened length of gestation and disruptions in fetal growth. Further,
the timing of exposure appears to be critical in determining the precise consequences to fetal
well-being. Nevertheless, no study has determined the effects of timing of exposure to stress
hormones on measurable characteristics of newborn physical and neuromuscular maturation,
independent of the effects of gestational length. Fetal exposure to stress hormones could lead
to at least two potential developmental trajectories for the fetus. First, fetal exposure to maternal
stress signals could prime fetal systems to mature more rapidly to ensure survival in anticipation
of a premature birth. This possibility is consistent with CRH-dependent accelerated
metamorphosis observed in tadpoles exposed to environmental stress that threatens survival
(Denver, 1997). The second possibility is that under stressful conditions, the fetus must
compete with its host (the mother) for resources required for coping and survival (Stearns,
2005). This possibility is consistent with findings indicating that fetal exposure to stress
hormones and synthetic corticosteroid administration are associated with fetal growth
restriction (Bloom et al., 2001; French et al., 1999; Reinisch et al., 1978; Wadhwa et al.,
2004). The purposes of the present study were to (1) test these competing hypotheses by
evaluating the consequences of exposure to stress hormones during pregnancy for physical and
neuromuscular development in infants and (2) determine the specific periods during pregnancy
during which stress hormones influence newborn physical and neuromuscular maturation.
METHODS
Participants
Participants in this study were part of the Multi-Site Behavior in Pregnancy Study (MS-BIPS),
which examined the effects of stress during pregnancy on birth outcomes. Four hundred ninety-
nine women with singleton, intrauterine pregnancies were recruited from 1997 to 2003 at two
major medical centers in Southern California. Ballard neonatal assessments were conducted
as part of routine neonatal care at only one site (UC Irvine), therefore the sample was limited
to this study site. The sample was comprised of 158 women and their infants. In addition, part
of the sample (89 women) was recruited earlier than 18 weeks’ gestation; therefore, an
additional earlier assessment was obtained for these women.
As presented in Table 1, the majority of the women were high school graduates, married, and
from middle-income households. The sample was ethnically and racially diverse, such that the
demographics were representative of pregnant women seen at this university hospital. Women
were not eligible for study participation if they had current or prior medical conditions related
to cardiovascular, neuroendocrine, hepatic, or renal functioning. In addition, women were
excluded if they had medical conditions that placed them at high-risk for adverse birth outcomes
(e.g., systemic maternal disease, placental or cord abnormalities, uterine anomalies, congenital
malformations, or chromosomal abnormalities) and if they smoked or used controlled
substances during or up to 3 months prior to their pregnancies.
As Table 1 indicates, the majority of the infants was born at term, was delivered vaginally, was
stable at delivery, and was approximately equally distributed in terms of sex.
Procedures
All procedures and methods were approved by the Institutional Review Boards of the
participating institutions and all women provided informed consent to participate in the study
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procedures. Blood samples were collected at four time points during gestation (15.10 ± 1.22;
19.20 ± 0.94; 24.85 ± 0.97; and 31.00 ± 0.88 weeks’ gestation). Samples were collected in the
afternoon (mean times (nautical hours): 15 weeks = 13:24; 19 weeks = 13:36, 25 weeks =
12:54, and 31 weeks = 13:14). A clinical ultrasound performed at the first study session
confirmed gestational age estimates based on last menstrual period. Infants were evaluated
with the New Ballard Neonatal Examination by attending physicians within 48 hr after birth
(mean 8.9 hr, SD = 7.94) to assess newborn physical and neuromuscular maturity.
Measures
Endocrine Assessments—Twenty-five milliliters of blood were collected through
antecubital venipuncture (within 20 s of venipuncture). Blood was deposited into siliconized
EDTA (purple top) vacutainers, placed on ice, and then centrifuged at 2000g (15 min). Plasma
was decanted into polypropylene tubes containing a protease inhibitor (500 KIU/mL aprotinin;
Sigma Chemical, St. Louis, MO) to arrest enzymatic degradation and then stored at −70°C
until assayed.
Unbound, bioactive placental CRH concentrations (pg/mL) were determined by
radioimmunoassay (RIA; Bachem Peninsula Laboratories, San Carlos, CA). Hypothalamic
CRH is not detectable in human peripheral sera; therefore, multiple studies have demonstrated
that CRH measured from maternal sera during pregnancy is from placental origins (King et
al., 2001; Lowry, 1993; Petraglia, Sawchenko, Rivier, & Vale, 1987; Petraglia, Sutton, & Vale,
1989). Plasma samples were extracted (1–2 mL) with 3 volumes of ice-cold methanol, mixed,
allowed to stand for 10 min at 4°C by the modified method of Linton et al. (1995). The pellets
were washed with 0.5 mL methanol and the combined supernatants were dried down on a
Savant SpeedVac Concentrator (Savant Instruments, Holbrook, NY). Reconstituted samples
in assay buffer were incubated in human anti-CRH serum for 48 hr at 4°C followed by a 24-
hr incubation period with 125I-CRH. Labeled and unlabeled CRH were collected by
immunoprecipitation with goat anti-rabbit IgG serum and normal rabbit serum after 90 min
incubation at room temperature. Samples were centrifuged at 1700g for 20 min at 4°C and the
aspirated pellets were quantified with a gamma scintillation counter. The CRH assay had less
than 0.01% cross-reactivity with ovine CRH, 36% cross-reactivity with bovine CRH, and
nondetectable reactivity with human adrenocorticotropic hormone (ACTH). The intra-assay
and inter-assay coefficients of variance ranged from 5% to 15%, respectively. Data reduction
for the RIA assay was performed with a computer assisted four-parameter logistics program
(Rodbard, Munson, & De Lean, 1978).
Plasma cortisol levels were determined by immunofluorescence using an automated procedure
on an Abbott TDx Analyzer (Abbott Laboratories, Abbot Park, IL). The assay was less than
5% cross-reactive with 11-deoxycortisol, corticosterone, and less than 1% cross-reactive with
10 other naturally occurring steroids. The inter- and intra-assay coefficients of variance were
less than 9% with a minimum detectable level of 0.45 μg/dL (95% confidence).
Newborn Physical and Neuromuscular Maturity—The New Ballard Maturation Score
was used to assess physical and neuromuscular maturation of the newborns used in this study
(Ballard et al., 1991). Although the New Ballard Score correlates with gestational age (r =
0.6807 in present study), about 54% of the variance in the Ballard Scores was not accounted
for by gestational age, indicating that the Ballard assesses infant maturation in a manner not
fully explained by length of gestation. Moreover, this is the first study to explore the
relationship between fetal exposure to stress hormones and infant maturation, using a measure
composed of multiple assessments of newborn characteristics that likely correspond to a better
metric of developmental age than gestational length. Specifically, the scoring uses
neuromuscular and physical characteristics of the newborn that develop over the course of
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gestation. The neuromuscular portion of the score consists of measures of muscle tone, distinct
posture, and angles of resistance in key muscle groups. For example, in extremely premature
infants flexibility is mostly absent at the wrist and passive flexor tone is mostly absent at the
knee, shoulder, and hip (Ballard et al., 1991). Physical characteristics examined in the New
Ballard Score include skin, lanugo, plantar surface of the foot, breast, eye/ear, and genitals.
These characteristics develop at distinct periods throughout gestation, such that extremely
premature infants typically have fused eyelids, sticky, transparent skin, no lanugo, absent breast
markings, and undifferentiated genitalia (Ballard et al., 1991). The New Ballard Scores range
from −10 to 50. In the present study, scores ranged from +12 to +49 (mean = 37.68, SD = 5.37).
Statistical Analyses—Statistical analyses were conducted using SAS version 8.2 software
(SAS, Inc., Cary, NC) and STATA version 8.1 (STATA Corporation, College Station, TX).
Initially, general multiple linear regression models were estimated for hormones at each study
time point to determine whether placental CRH and/or maternal cortisol were associated with
infant maturation, as assessed by the New Ballard Score. Models controlled for infant sex,
infant’s age at examination, parity, caesarian-section delivery, maternal age at delivery, and
ethnic/racial categories. Primiparity, or giving birth for the first time, and fetal sex have been
associated with differences in birth weight in previous studies; therefore parity and infant’s
sex were entered as covariates in all of the models (Ballard et al., 1991; Cogswell & Yip,
1995; Feldman, Dunkel-Schetter, Sandman, & Wadhwa, 2000; Lu & Halfon, 2003). Moreover,
ethnicity and race have been associated with changes in maternal cortisol and placental CRH
during pregnancy, as well as disparities in birth outcomes, such as low birth weight and
premature delivery (even after controlling for other risk factors, such as income, education,
parity, maternal age, and prenatal care; Glynn, Schetter, Chicz-DeMet, Hobel, & Sandman,
2007; Lu & Halfon, 2003). Given the aforementioned findings, analyses controlled for race/
ethnic categories, which consisted of non-Hispanic White, Latina, Asian, African American,
and other (multi-ethnic was combined with other due to small sample sizes). In addition,
infant’s age at exam, maternal age, and mode of delivery were significantly associated with
Ballard scores and other independent variables used in the models; therefore, these variables
were entered into the models to be conservative.
Additional models were constructed that controlled for gestational age at birth to assess whether
there were effects of stress hormones during pregnancy on fetal maturation, independent of the
length of gestation. Supplementary analyses were conducted separately for males and females
to determine whether fetal exposure to stress hormones differed by sex.
RESULTS
Results are displayed in Table 2. The findings indicated that increases in maternal cortisol at
15 and 19 weeks were associated significantly with decreases in infant physical and
neuromuscular maturation, with and without controlling for length of gestation. Without
controlling for length of gestation, every unit increase in maternal cortisol (μg/dL) at 15 and
19 weeks’ gestation was associated with a .411 decrease (p <.0001) and .148 (p = 0.026)
decrease in Ballard total scores, respectively. These results were consistent after controlling
for length of gestation, such that every unit increase in maternal cortisol (μg/dL) at 15 and 19
weeks’ gestation was associated with a .363 decrease (p <.0001) and .107 (p = 0.047) decrease
in Ballard total scores, respectively. In addition, maternal cortisol at 31 weeks was associated
with a significant increase in total Ballard scores, such that for every unit increase in maternal
cortisol (μg/dL) at 31 weeks, there was a .071 (p = .040) increase in total Ballard scores, without
controlling for gestational age at birth; however this result was nonsignificant after controlling
for length of gestation. In addition, placental CRH at 31 weeks was significantly associated
with decreases in infant physical and neuromuscular maturation. Specifically, each unit
increase in maternal placental CRH (pg/mL) was associated with a .006 decrease (p <.0001)
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in total neuromuscular/physical maturity. Moreover, this finding was statistically significant
after controlling for length of gestation (.005 decrease in total Ballard scores for every unit
increase in placental CRH; p <.0001).
In supplementary analyses examining male and female infants separately, results indicated that
the findings linking increases in maternal cortisol at 15 and 19 weeks and increases in placental
CRH at 31 weeks with decreases in infant physical and neuromuscular maturation only
remained significant for male infants (see Tab. 3). In addition, after separating analyses by
infant sex, every unit increase in maternal cortisol (μg/dL) at 25 weeks’ gestation was
associated with a .203 decrease (p = .036) in Ballard scores for males, but this finding was only
significant when controlling for length of gestation. Lastly, additional analyses suggested that
the relationship between increases in maternal cortisol at 31 weeks and increases in total Ballard
scores was restricted to female infants, which was only significant without controlling for
length of gestation (see Tab. 3).
DISCUSSION
The results of this study provide the first evidence that fetal exposure to increases in levels of
maternal cortisol at 15 and at 19 weeks and increases in levels of placental CRH at 31 weeks’
gestation are associated with significant decreases in newborn physical and neuromuscular
maturation. These effects were observed after controlling for length of gestation, indicating
that exposure to stress hormones portends poorer fetal maturation independent of maturation
effects associated with gestational age. These findings also suggest that intrauterine exposure
to certain key stress hormones influences the development of fetal systems that may have long-
term sequelae. For instance, decreased scores on newborn neuromuscular measures similar to
those used in the New Ballard Score have been associated with abnormalities detected with
MRI in newborns, including basal ganglia and white matter lesions, as well as motor
abnormalities that persist until age 4 in childhood (Haataja et al., 2001; Mercuri, Ricci, Pane,
& Baranello, 2005). Moreover, in newborns regarded as healthy by obstetric and pediatric staff,
deviant patterns on neurological examinations (including measures of posture, movement,
tone, reflexes, and some behavior) have been associated with newborn cranial ultrasound
abnormalities, including thalamic and peri-ventricular densities and intraventricular
hemorrhaging (Mercuri, Dubowitz, Brown, & Cowan, 1998). Hence, the findings of the present
study could have implications for neurobehavioral consequences in later development.
Further support for this possibility comes from animal studies (rats and rhesus monkeys) that
found alterations in multiple neuronal systems often persisting into adulthood following
exposure to stress hormones such as CRH and cortisol. Specifically, exposure to stress
hormones during the prenatal period has been associated with 50% increases in tyrosine
hydroxylase positive cells in the ventral tegmental area and the substantia nigra, as well as
increased dopamine D2-like receptors in the dorsal frontal cortex, medial prefrontal cortex,
hippocampus and nucleus accumbens in adult rat brains (Berger, Barros, Sarchi, Tarazi, &
Antonelli, 2002; McArthur, McHale, Dalley, Buckingham, & Gillies, 2005). Moreover, animal
findings suggest that fetal exposure to stress hormones leads to hippocampal abnormalities
(including cell death and reductions in cell proliferation) and corollary cognitive and behavioral
consequences, including deficits in learning and memory, long-lasting delays in neuromotor
development, distractibility, and increased ultrasonic vocalizations in response to maternal
separation (Brunson, Eghbal-Ahmadi, Bender, Chen, & Baram, 2001; Hennessy, Davis,
McCrea, Harvey, & Williams, 1999; Lemaire, Koehl, Le Moal, & Abrous, 2000; Roberts et
al., 2004). In humans, salivary cortisol in late pregnancy is associated with lower mental and
motor scores at 3 months and lower motor scores at 8 months (Huizink, Robles de Medina,
Mulder, Visser, & Buitelaar, 2003). Moreover, lower placental CRH at 25 weeks of gestation
predicted lower scores in infant fear and distress at 2 months of age (Davis et al., 2005).
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Findings from this study also indicated that there were differential effects of fetal exposure to
cortisol and CRH depending on the sex of the infant, such that fetal exposure to increases in
maternal cortisol at 15 and 19 weeks and fetal exposure to increases in placental CRH at 31
weeks was associated with decreased infant maturation only among male infants. Further,
increases in maternal cortisol at 25 weeks also led to decreased infant maturation among males,
suggesting that the effects of fetal exposure to maternal cortisol at this time point were obscured
by including female infants in initial analyses.
Multiple studies have found sex-specific effects of fetal exposure to maternal glucocorticoids
in animal and human models, although many of these findings produce contrary results to the
current study. Specifically, female rats appear to be more responsive to the effects of prenatal
exposure to maternal psychosocial stress (e.g., restraint), exhibiting hypocorticism over the
diurnal cycle, as well as increased ACTH and cortisol responses to restraint in adulthood
(Koehl et al., 1999; McCormick, Smythe, Sharma, & Meaney, 1995). Moreover, data from
mouse models suggest that there may be greater transport of corticosterone across the placenta
for female versus male fetuses (Montano, Wang, & vom Saal, 1993); however, female guinea
pigs exposed prenatally to dexamathasone showed increases in plasma cortisol levels only
during the follicular and luteal phases of the cycles, suggesting a potential influence of sex
steroids in the increased cortisol responses of females exposed to prenatal stress (Liu, Li, &
Matthews, 2001). Nevertheless, male pigs from mothers treated with ACTH expressed higher
corticosteroid-binding globulin (CBG), increased noradrenaline and increased brain
monoamine turnover, suggesting that the sex-specific effects of exposure to prenatal stress
hormones may vary depending on species (Kanitz, Otten, & Tuchscherer, 2006). Further,
human fetal plasma testosterone has been significantly correlated with fetal plasma cortisol
and male fetuses have significantly higher testosterone concentrations than female fetuses
(Gitau, Adams, Fisk, & Glover, 2005). Higher concentrations of testosterone among male
fetuses appear to be restricted to earlier periods of gestation, given that testosterone
concentrations increase throughout gestation among female fetuses and are similar in the two
sexes by term; therefore, the responsiveness of male fetuses to stress hormones in the current
study could be due to baseline higher concentrations of fetal cortisol and testosterone earlier
in gestation (Beck-Peccoz et al., 1991; Gitau et al., 2005).
The present study also found that maternal cortisol at 31 weeks was associated with significant
increases in newborn physical and neuromuscular maturation, which appeared to be restricted
to female infants. Although these effects were not significant after controlling for length of
gestation, these findings raise the possibility that exposure to maternal stress hormones may
have multiple consequences for the fetus, in some cases possibly leading to acceleration in
fetal maturation to ensure survival in anticipation of a premature birth (Denver, 1997). The
pattern of findings raises the possibility that not only does the timing of exposure to stress
hormones have consequences for fetal development, but the timing of the exposure may
differentially affect males and females. In light of this possibility, it is important to critically
examine the studies that have investigated sex-specific effects of fetal exposure to stress
hormones, given that the preponderance of these studies have limited the stress exposures to
mid to late gestation and/or throughout gestation in animal models, which may not map
precisely on to gestational periods of humans (Kanitz et al., 2006; Koehl et al., 1999; Liu et
al., 2001; McCormick et al., 1995; Montano et al., 1993).
In summary, the results from the present study indicate that fetal exposure to elevated levels
of maternal stress hormones early in pregnancy and placental stress hormones late in pregnancy
were associated with infant measures of maturation. These results are consistent with previous
results from our research group in which elevated levels of maternal cortisol at 15 weeks’
gestation was associated with a surge of placental CRH at 31 weeks’ gestation, which, in turn,
was associated with preterm delivery, suggesting that cortisol early in pregnancy primes the
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placenta later in pregnancy to initiate labor (Sandman et al., 2006). The present study found
that similar mechanisms may be involved in fetal growth and maturation, even after controlling
for the gestational length of the pregnancy, suggesting that an early maternal stress signal may
alter the dynamic interchange between the mother, the placenta, and the fetus over the course
of pregnancy, leading to fewer available resources for the fetus and poorer fetal maturation
(Stearns, 2005). These findings, in humans, suggest that the timing of exposure to stress
hormones is critical in determining the trajectory of fetal physical and neuromuscular
maturation. Furthermore, this is the first study to find that the timing of fetal exposure to stress
hormones has sex-specific effects on infant maturation, which calls for future studies to
examine the interactions between fetal exposure to stress hormones and sex-specific influences,
such as sex steroids. Lastly, future studies are necessary to elucidate whether stress hormones
interact with other potentially important systems, such as maternal nutritional intake and
metabolism, oxygen transfer to the fetus, and immune factors.
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Table 1
Subject Characteristics
Age (years) 30 ± 5.74
Marital status (% married) 74%
Education (%) 97% high school graduates
34.7% college graduates
Race/ethnicity (%) 45% non-Hispanic White
31% Latina
14% Asian
4% Multi-ethnic
3% African American
3% Other
Income $57, 662.34 ± $29, 351.20
Primiparous (%) 46%
Vaginal delivery (%) 67%
Infant male sex (%) 49%
Gestational age at birth 39 ± 1.84
1 min APGAR scores 8.16 ± 1.21
Data are presented as means ± standard deviations.
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